Sophiris Bio (SPHS) Upgraded to Sell by ValuEngine
ValuEngine upgraded shares of Sophiris Bio (NASDAQ:SPHS) from a strong sell rating to a sell rating in a research note issued to investors on Friday morning.
Several other equities analysts have also issued reports on the company. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a buy rating in a research report on Monday, December 11th. HC Wainwright reaffirmed a buy rating and issued a $6.00 price target on shares of Sophiris Bio in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $6.25.
Shares of Sophiris Bio (NASDAQ:SPHS) traded down $0.14 during mid-day trading on Friday, hitting $2.21. 764,794 shares of the stock were exchanged, compared to its average volume of 251,692. Sophiris Bio has a 1 year low of $1.80 and a 1 year high of $3.24. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.